English
中文简体
中文繁体
Company
Overview
Board of Directors
Partnering
Technology
Glycan-specific Conjugation
Alphatecan
Bispecific Antibody
Subcutaneous Formulation
Single-domain Antibody
Publications
Pipeline
Overview
Envafolimab(KN035)
KN026
JSKN003
JSKN016
JSKN033
KN046
KN019
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
Company
Overview
Board of Directors
Partnering
Technology
Glycan-specific Conjugation
Alphatecan
Bispecific Antibody
Subcutaneous Formulation
Single-domain Antibody
Publications
Pipeline
Overview
Envafolimab(KN035)
KN026
JSKN003
JSKN016
JSKN033
KN046
KN019
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
English
中文简体
中文繁体
Investors
Information Disclosure
Listing Documents
Financial Reports
Announcements & Circulars
Company Presentation
ESG Reports
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
Announcements & Circulars
The announcement begins in December 2019
2022 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
2023-04-27
GRANT OF SHARE OPTIONS
2023-04-25
CHANGE IN SHAREHOLDING STRUCTURE OF CONTROLLING SHAREHOLDERS
2023-04-21
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2023
2023-04-11
PROPOSED ADOPTION OF THE FIFTH AMENDED AND RESTATED ARTICLES OF ASSOCIATION
2023-03-31
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2022
2023-03-31
DATE OF BOARD MEETING
2023-03-16
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN A PHASE IA/IB CLINICAL TRIAL OF JSKN003 IN CHINA FOR THE TREATMENT OF HER2-EXPRESSING ADVANCED SOLID TUMORS
2023-03-15
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2023
2023-03-06
Next Day Disclosure Return
2023-02-09
8
9
10
11
12
13
14
PREV
11/27
NEXT
